Inclusion Criteria:

Histologic diagnosis of hepatocellular carcinoma The lesion or lesions are not resectable
with curative intent. Prior loco-regional treatment (resection, RFA, chemoembolization) is
allowed.

Adequate bone marrow function:

- Absolute neutrophil count (AGC) >1500/µL

- Platelet count >60,000 /µL

Renal function:

- Serum creatinine < 2.0 mg/dl, and a calculated CCT of > 30 mL/min. Hepatic
function:(Patients with a Child-Pugh (C-P) class A-B)

- Bilirubin < 2.8 mg/dl (provided the Child-Pugh class of liver cirrhosis is A or B
(7) (ie. The Child-Pugh score is only 7 points)

- ALT and AST ≤ 5.0 times the ULN • Hemoglobin > 8.5 g/dl

ECOG/Zubrod/SWOG Performance Status = 0>1 Life expectancy > 16 weeks Male or female' age
>18 years Patients of childbearing potential must be using an effective means of
contraception.

INR < 1.5 or a PT/PTT within normal limits.

Exclusion Criteria:

- Any prior systemic therapy including chemotherapy of targeted agents

- Uncontrolled ascites defined as not easily controlled by stable doses of diuretics.

- Pregnant or lactating females

- Cardiac disease: Congestive heart failure > class II NYHA. Patients must not have
unstable angina (anginal symptoms at rest) or new onset angina (began within the last
3 months) or myocardial infarction within the past 6 months.

- Uncontrolled' clinically significant dysrhythmia

- History of prior malignancy within the prior 3 years, with the exception of
non-melanoma carcinomas of the skin, carcinoma in situ of the cervix or breast, Rai
Stage I chronic lymphocytic leukemia and superficial bladder cancer.

- Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor
growth in that lesion

- Uncontrolled metastatic disease of the central nervous system

- Radiotherapy within the 2 weeks before Cycle 1' Day 1

- Surgery within the 2 weeks before Cycle 1' Day 1

- Any co morbid condition that' in the view of the attending physician' renders the
patient at high risk from treatment complications.

- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic
pressure > 90 mmHg, despite optimal medical management.

- Known human immunodeficiency virus (HIV) infection.

- Patients with chronic Hepatitis B or C infections are eligible.

- Active clinically serious infection > CTCAE Grade 2.

- Thrombolic or embolic events such as a cerebrovascular accident including transient
ischemic attacks within the past 6 months.

- Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of
study drug.

- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of
study drug.

- Serious non-healing wound, ulcer, or bone fracture.

- Evidence or history of bleeding diathesis or coagulopathy.

- Use of St. John's Wort or rifampin (rifampicin).

- Known or suspected allergy to sorafenib or any agent given in the course of this
trial.

- Any condition that impairs patient's ability to swallow whole pills.

- Any malabsorption problem.